Publications
2024
Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.
Wooding, D., Buist, K., Romero-Ramirez, A., Savage, H., Watkins, R., Bengey, D., . . . Edwards, T. (2024). Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.. mSphere, e0030424. doi:10.1128/msphere.00304-24
Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.
Else, L. J., Dickinson, L., Edick, S., Zyhowski, A., Ho, K., Meyn, L., . . . Brand, R. M. (2024). Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.. The Journal of antimicrobial chemotherapy, 79(7), 1597-1605. doi:10.1093/jac/dkae147
Optimisation of SARS-CoV-2 culture from clinical samples for clinical trial applications
2023
K-Ras independence due to N-Ras expression in cancer cell lines giving resistance to K-Ras specific inhibitors
Ferguson, R., Aughton, K., Evans, A., Shaw, V., Costello, E., & Greenhalf, W. (2023). K-Ras independence due to N-Ras expression in cancer cell lines giving resistance to K-Ras specific inhibitors. Pancreatology, 23, e149. doi:10.1016/j.pan.2023.06.783
Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.
Roper, K. J., Thomas, J., Albalawi, W., Maddocks, E., Dobson, S., Alshehri, A., . . . Pollakis, G. (2023). Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.. Scientific reports, 13(1), 15014. doi:10.1038/s41598-023-41928-2
Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
Ferguson, R., Aughton, K., Evans, A., Shaw, V., Armstrong, J., Ware, A., . . . Greenhalf, W. (2023). Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. CURRENT ISSUES IN MOLECULAR BIOLOGY, 45(3), 2505-2520. doi:10.3390/cimb45030164
Wild-type N-Ras Complements Mutant K-Ras in Pancreatic Cancer Cell Lines but K-Ras has a Specific Role in Cell Cycle Independent Regulation of G2 Cyclins
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N., . . . Openshaw, P. J. M. (2023). SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBIOMEDICINE, 87. doi:10.1016/j.ebiom.2022.104402
2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
Donovan-Banfield, I., Penrice-Randal, R., Goldswain, H., Rzeszutek, A. M., Pilgrim, J., Bullock, K., . . . Fletcher, T. (2022). Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. NATURE COMMUNICATIONS, 13(1). doi:10.1038/s41467-022-34839-9
Wild-type N-Ras Complements Mutant K-Ras in Pancreatic Cancer Cell Lines but K-Ras has a Specific Role in Cell Cycle Independent Regulation of G2 Cyclins
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., . . . Vyas, A. (2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(22)00644-2
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
Siggins, M. K., Davies, K., Fellows, R., Thwaites, R. S., Baillie, J. K., Semple, M. G., . . . ISARIC4C Investigators. (2022). Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology. doi:10.1111/imm.13585
Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number
Keeling, M. J., Dyson, L., Guyver-Fletcher, G., Holmes, A., Semple, M. G., Tildesley, M. J., & Hill, E. M. (2022). Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. STATISTICAL METHODS IN MEDICAL RESEARCH, 31(9), 1716-1737. doi:10.1177/09622802211070257
Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study
Millar, J. E., Neyton, L., Seth, S., Dunning, J., Merson, L., Murthy, S., . . . Baillie, J. K. (2022). Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. SCIENTIFIC REPORTS, 12(1). doi:10.1038/s41598-022-08032-3
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199
2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318
A prenylated dsRNA sensor protects against severe COVID-19
Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., . . . Wilson, S. J. (2021). A prenylated dsRNA sensor protects against severe COVID-19. SCIENCE, 374(6567). doi:10.1126/science.abj3624
Investigation of SARS-CoV-2 faecal shedding in the community: a prospective household cohort study (COVID-LIV) in the UK
Vaselli, N. M., Setiabudi, W., Subramaniam, K., Adams, E. R., Turtle, L., Iturriza-Gomara, M., . . . Hungerford, D. (2021). Investigation of SARS-CoV-2 faecal shedding in the community: a prospective household cohort study (COVID-LIV) in the UK. BMC INFECTIOUS DISEASES, 21(1). doi:10.1186/s12879-021-06443-7
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., . . . Ho, A. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. LANCET MICROBE, 2(8), E354-E365. doi:10.1016/S2666-5247(21)00090-2
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK
Docherty, A., Mulholland, R., Lone, N. I., Cheyne, C., De Angelis, D., Diaz-Ordaz, K., . . . Semple, M. (2021). Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 773-785. doi:10.1016/S2213-2600(21)00175-2
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.
Drake, T. M., Fairfield, C. J., Pius, R., Knight, S. R., Norman, L., Girvan, M., . . . ISARIC4C Investigators. (2021). Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.. The Lancet. Rheumatology, 3(7), e498-e506. doi:10.1016/s2665-9913(21)00104-1
Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort
Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK
Bloom, C. I., Drake, T. M., Docherty, A. B., Lipworth, B. J., Johnston, S. L., Nguyen-Van-Tam, J. S., . . . Openshaw, P. J. M. (2021). Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 699-711. doi:10.1016/S2213-2600(21)00013-8
Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England
Leclerc, Q. J., Fuller, N. M., Keogh, R. H., Diaz-Ordaz, K., Sekula, R., Semple, M. G., . . . Knight, G. M. (2021). Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC HEALTH SERVICES RESEARCH, 21(1). doi:10.1186/s12913-021-06509-x
Going viral: misinformation in the time of COVID-19
Going viral: misinformation in the time of COVID-19 (2021). LANCET RHEUMATOLOGY, 3(6), E393. doi:10.1016/S2665-9913(21)00104-1
Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol
Setiabudi, W., Hungerford, D., Subramaniam, K., Vaselli, N. M., Shaw, V. E., Wilton, M., . . . French, N. (2021). Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol. BMJ Open, 11(3), e048317. doi:10.1136/bmjopen-2020-048317
2020
A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (vol 10, 1796, 2020)
McWilliam, S. J., Rosala-Hallas, A., Jones, A. P., Shaw, V., Greenhalf, W., Jaki, T., . . . Pirmohamed, M. (2020). A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (vol 10, 1796, 2020). SCIENTIFIC REPORTS, 10(1). doi:10.1038/s41598-020-61783-9
A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis.
McWilliam, S. J., Rosala-Hallas, A., Jones, A. P., Shaw, V., Greenhalf, W., Jaki, T., . . . Pirmohamed, M. (2020). A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis.. Scientific reports, 10(1). doi:10.1038/s41598-020-58790-1
2018
Biomarker predication of efficacy to gemcitabine plus vandetanib in phase II, double blind multicentre randomised controlled trial of gemcitabine placebo in locally advanced or metastatic pancreatic carcinoma
Evans, A., Jackson, R., Shaw, V. E., Ghaneh, P., Wadsley, J., Valle, J. W., . . . Middleton, G. (2018). Biomarker predication of efficacy to gemcitabine plus vandetanib in phase II, double blind multicentre randomised controlled trial of gemcitabine placebo in locally advanced or metastatic pancreatic carcinoma. Pancreatology, 18(4), S127-S128. doi:10.1016/j.pan.2018.05.343
2017
Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.
Neoptolemos, J. P., Palmer, D., Greenhalf, W., Ghaneh, P., Jackson, R., Evans, A., . . . Middleton, G. W. (2017). Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.15_suppl.4104
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., . . . Neoptolemos, J. P. (2017). Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18(4), 486-499. doi:10.1016/S1470-2045(17)30084-0
2016
miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer
Muehlberg, L., Kuehnemuth, B., Costello, E., Shaw, V., Sipos, B., Huber, M., . . . Michl, P. (2016). miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. ONCOIMMUNOLOGY, 5(6). doi:10.1080/2162402X.2016.1160181
Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia
Demir, I. E., Tieftrunk, E., Schorn, S., Saricaoglu, O. C., Pfitzinger, P. L., Teller, S., . . . Ceyhan, G. O. (2016). Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. GUT, 65(6), 1001-1014. doi:10.1136/gutjnl-2015-309784
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
Middleton, G., Greenhalf, W., Costello, E., Shaw, V., Cox, T., Ghaneh, P., . . . Neoptolemos, J. P. (2016). Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. British Journal of Cancer, 114, 510-518. doi:10.1038/bjc.2015.468
Single-Nucleotide Polymorphism to Associate Cancer Risk
Shaw, V., Bullock, K., & Greenhalf, W. (2016). Single-Nucleotide Polymorphism to Associate Cancer Risk. CANCER GENE PROFILING, 1381, 93-110. doi:10.1007/978-1-4939-3204-7_6
2015
Post-translational modifications of ribonucleotide reductase can explain acquired gemcitabine resistance in pancreatic cancer
Mann, K., Melling, J., Rogoyski, B., Shaw, V., Ghaneh, P., & Greenhalf, W. (2015). Post-translational modifications of ribonucleotide reductase can explain acquired gemcitabine resistance in pancreatic cancer. Pancreatology, 15(3), S20. doi:10.1016/j.pan.2015.05.105
miRNA-21 modulates tumour progression by altering the functional phenotype of tumour-associated macrophages in pancreatic cancer
Muehlberg, L., Kuehnemuth, B., Costello, E., Shaw, V., Griesmann, H., Egidi, M., . . . Michl, P. (2015). miRNA-21 modulates tumour progression by altering the functional phenotype of tumour-associated macrophages in pancreatic cancer. Pancreatology, 15(3), S41-S42. doi:10.1016/j.pan.2015.05.173
2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Middleton, G., Silcocks, P., Cox, T. F., Valle, J., Wadsley, J., Propper, D., . . . Neoptolemos, J. P. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology, 15(8), 829-840. doi:10.1016/S1470-2045(14)70236-0
Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial
Neoptolemos, J. P., Greenhalf, W., Cox, T. F., Costello, E., Shaw, V., Valle, J. W., . . . Middleton, G. (2014). Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 4121). doi:10.1200/jco.2014.32.15_suppl.4121
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.. Molecular cancer, 13, 114. doi:10.1186/1476-4598-13-114
Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T. F., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease. Molecular Cancer, 13. Retrieved from https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-114
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer
Annels, N. E., Shaw, V. E., Gabitass, R. F., Billingham, L., Corrie, P., Eatock, M., . . . Middleton, G. (2014). The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. CANCER IMMUNOLOGY IMMUNOTHERAPY, 63(2), 175-183. doi:10.1007/s00262-013-1502-y
2013
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
Middleton, G. W., Valle, J. W., Wadsley, J., Propper, D., Coxon, F. Y., Ross, P. J., . . . Neoptolemos, J. P. (2013). A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 31(18_suppl), LBA4004. doi:10.1200/jco.2013.31.18_suppl.lba4004
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
Middleton, G. W., Valle, J. W., Wadsley, J., Propper, D., Coxon, F. Y., Ross, P. J., . . . Neoptolemos, J. P. (2013). A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 31(15_suppl), LBA4004. doi:10.1200/jco.2013.31.15_suppl.lba4004
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
Tonack, S., Jenkinson, C., Cox, T., Elliott, V., Jenkins, R. E., Kitteringham, N. R., . . . Costello, E. (2013). iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. BRITISH JOURNAL OF CANCER, 108(9), 1846-1853. doi:10.1038/bjc.2013.150
Quantification of pancreatic ductal adenocarcinoma stroma
Hand, K., Oldfield, F., Shaw, V., Jenkinson, C., Campbell, F., Neoptolemos, J., . . . Greenhalf, W. (2013). Quantification of pancreatic ductal adenocarcinoma stroma. Pancreatology, 13(3), S28. doi:10.1016/j.pan.2013.04.088
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
Tonack, S., Jenkinson, C., Cox, T., Elliott, V., Jenkins, R. E., Kitteringham, N. R., . . . Costello, E. (2013). iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. British Journal of Cancer, 108(9), 1846-1853. doi:10.1038/bjc.2013.150
2012
Combination cytokine, chemokine and growth factor biomarkers for diagnosis of pancreatic cancer
Shaw, V. E., Jenkinson, C., Lane, B., Greenhalf, B., Neoptolemos, J. P., & Costello, E. (2012). Combination cytokine, chemokine and growth factor biomarkers for diagnosis of pancreatic cancer. Pancreatology, 12(6), 545. doi:10.1016/j.pan.2012.11.148
2010
Abstract P2-09-37: Immunohistochemical Markers Progesterone Receptor, HER2, Ki67 and bcl-2-Associated Athanogene 1 and Prediction of Adjuvant Tamoxifen Treatment Outcome in ER+ Early Breast Cancer
Gee, J. M., Aleskandarany, M. A., Finlay, P., Farrow, L., Nicholson, R. I., Habashy, H. O., . . . Ellis, I. O. (2010). Abstract P2-09-37: Immunohistochemical Markers Progesterone Receptor, HER2, Ki67 and bcl-2-Associated Athanogene 1 and Prediction of Adjuvant Tamoxifen Treatment Outcome in ER+ Early Breast Cancer. Cancer Research, 70(24_Supplement). doi:10.1158/0008-5472.sabcs10-p2-09-37
Diagnostic Markers of Pancreatic Cancer: Serum Cytokines, Chemokines, and Growth Factors
Fung Tang, J. M., Shaw, V., Jenkinson, C., Greenhalf, W., Neoptolemos, J., & Costello, E. (2010). Diagnostic Markers of Pancreatic Cancer: Serum Cytokines, Chemokines, and Growth Factors. European Journal of Surgical Oncology, 36(11), 1096. doi:10.1016/j.ejso.2010.08.093
Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer
Shaw, V. E., Naisbitt, D. J., Costello, E., Greenhalf, W., Park, B. K., Neoptolemos, J. P., & Middleton, G. W. (2010). Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. EXPERT REVIEW OF VACCINES, 9(9), 1007-1016. doi:10.1586/ERV.10.92
2009
The Dark Side of Antihormonal Action in Breast Cancer
Gee, J. M. W., Stone, A., McClelland, R. A., Hiscox, S., Hutcheson, I. R., Jordan, N. J., . . . Nicholson, R. I. (n.d.). The Dark Side of Antihormonal Action in Breast Cancer. In Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer (pp. 63-84). Springer Netherlands. doi:10.1007/978-1-4020-8526-0_4
2008
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells
Borley, A. C., Hiscox, S., Gee, J., Smith, C., Shaw, V., Barrett-Lee, P., & Nicholson, R. I. (2008). Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. BREAST CANCER RESEARCH, 10(6). doi:10.1186/bcr2206
2006
Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications
Gee, J. M. W., Shaw, V. E., Hiscox, S. E., McClelland, R. A., Rushmere, N. K., & Nicholson, R. I. (2006). Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. ENDOCRINE-RELATED CANCER, 13, S77-S88. doi:10.1677/erc.1.01274